Alerus Financial’s Cartesian Therapeutics RNAC Stock Holding History

Alerus Financial’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.15K	Hold	1,000	–	–	﹤0.01%	411
2025 Q4	$7.21K	Hold	1,000	–	–	﹤0.01%	378
2025 Q3	$10.2K	Hold	1,000	–	–	﹤0.01%	376
2025 Q2	$10.4K	Buy	+1,000	New	+$10.7K	﹤0.01%	359
2024 Q2	–	Sell	-1,000	Closed	-$19.5K	–	167
2024 Q1	$19.5K	Hold	1,000	–	–	﹤0.01%	161
2023 Q4	$20.7K	Hold	1,000	–	–	﹤0.01%	149
2023 Q3	$31.8K	Hold	1,000	–	–	﹤0.01%	150
2023 Q2	$33.6K	Hold	1,000	–	–	﹤0.01%	155
2023 Q1	$41.7K	Hold	1,000	–	–	﹤0.01%	161
2022 Q4	$33.9K	Hold	1,000	–	–	﹤0.01%	161
2022 Q3	$49K	Hold	1,000	–	–	﹤0.01%	147
2022 Q2	$39K	Buy	1,000 +667	+200%	+$19.8K	﹤0.01%	162
2022 Q1	$12K	Hold	333	–	–	﹤0.01%	178
2021 Q4	$33K	Hold	333	–	–	﹤0.01%	182
2021 Q3	$42K	Hold	333	–	–	﹤0.01%	181
2021 Q2	$42K	Hold	333	–	–	﹤0.01%	190
2021 Q1	$45K	Buy	+333	New	+$41.3K	﹤0.01%	184

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alerus Financial's RNAC Position: Q1 2026 in Review

Alerus Financial held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 1,000 shares worth $6.15K. The position accounts for ﹤0.01% of the portfolio, ranked #411.

Alerus Financial first reported a position in RNAC in Q1 2021 and has held it in 17 quarters since. The position peaked at $49K in Q3 2022. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Alerus Financial held 1,000 shares of Cartesian Therapeutics worth $6.15K as of Q1 2026.
Alerus Financial left its Cartesian Therapeutics share count unchanged in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of Alerus Financial's portfolio in Q1 2026, its #411 holding.
Alerus Financial first reported a position in Cartesian Therapeutics in Q1 2021 and has held it in 17 quarters since.
Alerus Financial's Cartesian Therapeutics position peaked at $49K in Q3 2022.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Alerus Financial's 13F filing for Q1 2026, filed 12 May 2026.